SIGA
vs
S&P 500
SIGA
S&P 500
Over the past 12 months, SIGA has underperformed S&P 500, delivering a return of +5% compared to the S&P 500's +12% growth.
Stocks Performance
SIGA vs S&P 500
Performance Gap
SIGA vs S&P 500
Performance By Year
SIGA vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
SIGA Technologies Inc
Glance View
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The company is headquartered in New York City, New York and currently employs 39 full-time employees. The Company’s lead product, TPOXX (oral TPOXX), is an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The firm does not have a manufacturing infrastructure and does not intend to develop one for the manufacture of TPOXX. The company uses contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company’s CMOs apply methods and controls in facilities, which are uses for manufacturing, processing, packaging, testing, analyzing and holding pharmaceuticals, which conform to current good manufacturing practices (cGMP), the standard set by the FDA for manufacture and storage of pharmaceuticals intended for human use. For the manufacture of oral TPOXX, the Company uses the four CMOs, namely W.R. Grace and Company; Powdersize, LLC; Catalent Pharma Solutions LLC, and Packaging Coordinators, LLC.
